Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 8, 2025

MongoDB and Bath & Body Works have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
MongoDB and Bath & Body Works have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – December 8, 2025 – Zacks Equity Research shares MongoDB MDB as the Bull of the Day and Bath & Body Works, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Top stock-picking strategies have blown away the S&P's +7.7% average gain per year with average gains of +48.4%, +50.2% and +56.7% per year since 2000

    80% confidence
  • MDB shares are a buy

    80% confidence
  • Company expects EPS growth of ~30% and revenue growth of 20%

    80% confidence
  • Q4 sales were down in the high single digits

    80% confidence
  • North American consumers are spending less on non-essential home products

    80% confidence
  • MongoDB has surpassed Zacks Consensus Analyst Estimates by 69.30% over the past four quarters

    80% confidence
  • Zacks Consensus Analyst Estimates suggest negative earnings growth over the next two years for Bath & Body Works

    80% confidence
  • Performance would have been worse had it not been for an extended fall sale

    80% confidence
  • Bath & Body Works' core demand engine is weakening, signaling erosion in brand relevance and consumer engagement

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com